Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESTRO 2026 | Which patients with kidney cancer may benefit from SABR treatment?

Shankar Siva • 16 May 2026
ESTRO 2026
Genitourinary Cancer Kidney Cancer

Shankar Siva, PhD, MBBS, FRANZCR, Peter MacCallum Cancer Centre and Royal Hospital Melbourne, Melbourne, Australia, discusses which kidney cancer patients may be suitable for treatment with stereotactic ablative body radiotherapy (SABR), which is currently indicated for patients not eligible for or at high-risk from surgery. Prof. Siva also highlights patients with large or complex tumors, who may also benefit from the higher precision targeting that SABR allows. In the future, SABR could be used to avoid a radical or total nephrectomy in certain patients. This interview took place at the European Society for Radiotherapy and Oncology 2026 Congress in Stockholm, Sweden.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Shankar Siva

How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Long-term results from FASTRACK II: SABR for primary kidney cancer
2:15
Long-term results from FASTRACK II: SABR for primary kidney cancer
Shankar Siva • 16 May 2026
The importance of radiation dose and quality in improving outcomes for patients with NSCLC
1:03
The importance of radiation dose and quality in improving outcomes for patients with NSCLC
Shankar Siva • 31 May 2025
Evaluating atezolizumab in early-stage and limited-stage lung cancer
3:55
Evaluating atezolizumab in early-stage and limited-stage lung cancer
Shankar Siva • 31 May 2025

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026
Emotional health burden and unmet support needs in kidney cancer
2:19
Emotional health burden and unmet support needs in kidney cancer
Eric Jonasch • 30 May 2026
The content of VJOncology is intended for healthcare professionals